Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Total Non-Current Liabilities (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 29.61% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 29.61% increase, with the full-year FY2025 number at $5.9 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $5.7 million for Q4 2025 at Neuphoria Therapeutics, down from $6.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $6.7 million in Q3 2025 to a low of $3.6 million in Q2 2022.
  • A 4-year average of $5.0 million and a median of $5.1 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: increased 5.99% in 2023, then rose 29.61% in 2025.
  • Neuphoria Therapeutics' Total Non-Current Liabilities stood at $3.6 million in 2022, then grew by 5.99% to $3.8 million in 2023, then increased by 15.4% to $4.4 million in 2024, then increased by 29.61% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Total Non-Current Liabilities are $5.7 million (Q4 2025), $6.7 million (Q3 2025), and $5.9 million (Q2 2025).